C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFRT790M mutant-Reference-Cited by-全球学者库

C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFRT790M mutant

Published:2015 Issue:9 Volume:6 Page:1693-1697
ISSN:2040-2503
Container-title:MedChemComm
language:en
Short-container-title:Med. Chem. Commun.

Author:

Xu Tianfeng¹²³⁴⁵,Peng Ting⁶⁷³⁸⁵,Ren Xiaomei¹²³⁴⁵,Zhang Lianwen¹²³⁴⁵,Yu Lei¹²³⁴⁵,Luo Jinfeng¹²³⁴⁵,Zhang Zhang¹²³⁴⁵,Tu Zhengchao¹²³⁴⁵,Tong Linjiang⁶⁷³⁸⁵,Huang Zhaoru⁶⁷³⁸⁵,Lu Xiaoyun¹²³⁴⁵,Geng Meiyu⁶⁷³⁸⁵,Xie Hua⁶⁷³⁸⁵,Ding Jian⁶⁷³⁸⁵,Ding Ke¹²³⁴⁵

Affiliation:

1. State Key Laboratory of Respiratory Diseases

2. Guangzhou Institute of Biomedicine and Health

3. Chinese Academy of Sciences

4. Guangzhou 510530

5. China

6. State Key Laboratory of Drug Research

7. Shanghai Institute of Materia Medica

8. Shanghai 201203

Abstract

C5-substituted pyrido[2,3-d]pyrimidin-7-ones were discovered as highly potent and specific inhibitors targeting the clinical resistance-related EGFR^L858R/T790M mutant.

Funder

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Subject

Pharmaceutical Science,Biochemistry,Drug Discovery,Molecular Medicine,Pharmacology,Organic Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2015/MD/C5MD00208G

Reference38 articles.

1. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

3. Afatinib: A Review of Its Use in the Treatment of Advanced Non-Small Cell Lung Cancer